Full history for every metric is available with a Kvantra account
Theradiag S.A. (ALTER.PA)
Key financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 9 | 9 | 3 | 10 | 11 | 12 | 14 |
| Operating profit | €m | -0 | 1 | |||||
| Net profit | €m | -6 | -1 | -4 | -0 | -1 | -0 | 0 |
| EPS reported | € | -0.04 | 0.03 | |||||
| Operating cashflow per share | € | 0.00 | 0.00 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | 0.00 | 0.00 | |||||
| Free cash flow | €m | 0 | 0 | |||||
| Net debt | €m | -5 | -4 | |||||
| Book value equity | €m | 8 | 9 | |||||
| Book value per share | € | 0.65 | 0.71 | |||||
| Number of shares | m | 13.01 | 13.05 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 3.51 | 1.86 | |||||
| P/S LTM | x | 2.43 | 1.28 | |||||
| P/FCF LTM | x | 0.00 | 0.00 | |||||
| EV/EBITDA LTM | x | 102.35 | 11.39 | |||||
| EV/Sales LTM | x | 2.06 | 0.98 | |||||
| Earnings Yield LTM | % | -1.64% | -2.98% | |||||
| FCF Yield | % | 0.00% | 0.00% | |||||
| Quality | ||||||||
| ROE | % | -5.77% | -5.61% | |||||
| ROIC | % | -1.62% | -1.62% | |||||
| Operating margin | % | -2.25% | -2.25% | |||||
| Gross margin | % | 44.81% | 44.81% | |||||
| FCF/Sales | % | 0.00% | 0.00% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +9.71% | +5.65% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.00 | 0.00 | |||||
| Net Debt/EBITDA | x | -18.57 | -18.57 | |||||
| EBIT/Net interest | x | -3.12 | -3.12 | |||||
| Net debt/market cap | % | -15.36% | -23.61% | |||||
| Net debt/Equity | x | -0.54 | -0.44 | |||||
| Gross debt/equity | x | 0.22 | 0.17 | |||||
Company overview
Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Theradiag S.A. (ALTER.PA)
Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free